Investor Presentaiton
TIGIT Cluster: IBI-939 (TIGIT mAb) and IBI-321 (PD-1/TIGIT
Bispecific Antibody)
IBI-939 Preclinical Highlights
IBI-321 Preclinical Highlights
•
IBI-939 is fully human antibody with high TIGIT binding affinity and
strong ligand blocking activity
•
Combining PD-1 and TIGIT inhibition to release PD-1/PD-L1 as well as
TIGIT/PVR inhibition of intratumoral T/NK cells, to enhance T/NK-cell
mediated anti-tumor efficacy
•
IBI-939 exhibited strong anti-tumor activities as monotherapy or in
combination with anti-PD-1 antibody in different tumor models
IBI-939 Development Program Overview
•
Bridge PD-1 and TIGIT on the same cell (T cells, NK cells) to maximal
activation of CD226/PVR and relieve tumor immunosuppression
IBI-321 Development Program Overview
•
Started Phase 1a study for IBI-939 in 2020
Clinical
Clinical
•
progress
Started Phase 1b for IBI-939 in combination with sintilimab for
advanced lung cancer in early 2021
progress
•
Plan to complete the Phase 1b study in 2021
.
2021 plan
Plan to publish the preliminary Phase 1 study result of IBI-939 in
2021
2021 plan
Global development plan ongoing
IND application for IBI-321 accepted by NMPA in early 2021
Plan to receive IND approval for IBI-321 in 2021
Plan to start Phase 1 clinical study for IBI-321 in 2021
Leading and highly differentiated position in TIGIT area: IBI-939 as domestic leading TIGIT mAb under development, and
IBI-321 (PD-1/TIGIT) heading into clinical stage with novel biological mechanism and potential strong synergy.
Innovent
Confidential
Copyright©2021 Innovent Biologics
27View entire presentation